Recently, Hexin Biopharmaceutical (Changchun) Co., Ltd. received thrilling news: its independently developed anti-tumor drug XY003 has successfully obtained clinical trial approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration!
XY003 is a new mechanism cancer drug that utilizes synthetic lethality to eliminate DNA damage repair-deficient tumors. It can be used for the treatment of advanced malignant tumors such as breast cancer and pancreatic cancer. Its efficacy surpasses that of PARP inhibitor drugs and is broader in scope, capable of treating certain advanced solid tumors that are insensitive to or have developed resistance to PARP inhibitors. This approval marks a solid step forward for the company in the field of anti-tumor drug development, bringing new hope for treatment to patients with advanced solid tumors.
Founded in August 2020, Hexin Biopharmaceutical (Changchun) Co., Ltd. boasts a high-level international R&D team led by overseas PhD scientists, dedicated to developing First-in-Class and Best-in-Class innovative cancer drugs, antiviral drugs, and diagnostic methods. The drug targets are highly innovative, representing a new class of drugs, and are at the forefront domestically and leading globally.
The company also develops new antiviral drugs against herpes, surpassing the efficacy of market-leading drugs like Ganciclovir. Its microbial detection methods are convenient and rapid, widely used in pharmaceutical companies, households, livestock, food, and environmental monitoring.
The approval of this IND not only recognizes the research capabilities of Hexin Biopharmaceutical (Changchun) Co., Ltd. but also highly affirms its innovation in new drug development. The company will continue to uphold the spirit of "innovation, quality, responsibility," accelerating the clinical trial process of the XY003 project, striving to bring this innovative drug to market as soon as possible, and providing more effective treatment options for patients.